Cargando…

Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders

[Image: see text] Retinoic acid receptor-related orphan receptor γ-t (RORγt) and GPBAR1, a transmembrane G-protein-coupled receptor for bile acids, are attractive drug targets to develop clinically relevant small modulators as potent therapeutics for autoimmune diseases. Herein, we designed, synthes...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorillo, Bianca, Roselli, Rosalinda, Finamore, Claudia, Biagioli, Michele, di Giorgio, Cristina, Bordoni, Martina, Conflitti, Paolo, Marchianò, Silvia, Bellini, Rachele, Rapacciuolo, Pasquale, Cassiano, Chiara, Limongelli, Vittorio, Sepe, Valentina, Catalanotti, Bruno, Fiorucci, Stefano, Zampella, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933477/
https://www.ncbi.nlm.nih.gov/pubmed/36816679
http://dx.doi.org/10.1021/acsomega.2c07907
_version_ 1784889686382084096
author Fiorillo, Bianca
Roselli, Rosalinda
Finamore, Claudia
Biagioli, Michele
di Giorgio, Cristina
Bordoni, Martina
Conflitti, Paolo
Marchianò, Silvia
Bellini, Rachele
Rapacciuolo, Pasquale
Cassiano, Chiara
Limongelli, Vittorio
Sepe, Valentina
Catalanotti, Bruno
Fiorucci, Stefano
Zampella, Angela
author_facet Fiorillo, Bianca
Roselli, Rosalinda
Finamore, Claudia
Biagioli, Michele
di Giorgio, Cristina
Bordoni, Martina
Conflitti, Paolo
Marchianò, Silvia
Bellini, Rachele
Rapacciuolo, Pasquale
Cassiano, Chiara
Limongelli, Vittorio
Sepe, Valentina
Catalanotti, Bruno
Fiorucci, Stefano
Zampella, Angela
author_sort Fiorillo, Bianca
collection PubMed
description [Image: see text] Retinoic acid receptor-related orphan receptor γ-t (RORγt) and GPBAR1, a transmembrane G-protein-coupled receptor for bile acids, are attractive drug targets to develop clinically relevant small modulators as potent therapeutics for autoimmune diseases. Herein, we designed, synthesized, and evaluated several new bile acid-derived ligands with potent dual activity. Furthermore, we performed molecular docking and MD calculations of the best dual modulators in the two targets to identify the binding modes as well as to better understand the molecular basis of the inverse agonism of RORγt by bile acid derivatives. Among these compounds, 7 was identified as a GPBAR1 agonist (EC(50) 5.9 μM) and RORγt inverse agonist (IC(50) 0.107 μM), with excellent pharmacokinetic properties. Finally, the most promising ligand displayed robust anti-inflammatory activity in vitro and in vivo in a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis.
format Online
Article
Text
id pubmed-9933477
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-99334772023-02-17 Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders Fiorillo, Bianca Roselli, Rosalinda Finamore, Claudia Biagioli, Michele di Giorgio, Cristina Bordoni, Martina Conflitti, Paolo Marchianò, Silvia Bellini, Rachele Rapacciuolo, Pasquale Cassiano, Chiara Limongelli, Vittorio Sepe, Valentina Catalanotti, Bruno Fiorucci, Stefano Zampella, Angela ACS Omega [Image: see text] Retinoic acid receptor-related orphan receptor γ-t (RORγt) and GPBAR1, a transmembrane G-protein-coupled receptor for bile acids, are attractive drug targets to develop clinically relevant small modulators as potent therapeutics for autoimmune diseases. Herein, we designed, synthesized, and evaluated several new bile acid-derived ligands with potent dual activity. Furthermore, we performed molecular docking and MD calculations of the best dual modulators in the two targets to identify the binding modes as well as to better understand the molecular basis of the inverse agonism of RORγt by bile acid derivatives. Among these compounds, 7 was identified as a GPBAR1 agonist (EC(50) 5.9 μM) and RORγt inverse agonist (IC(50) 0.107 μM), with excellent pharmacokinetic properties. Finally, the most promising ligand displayed robust anti-inflammatory activity in vitro and in vivo in a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. American Chemical Society 2023-01-31 /pmc/articles/PMC9933477/ /pubmed/36816679 http://dx.doi.org/10.1021/acsomega.2c07907 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Fiorillo, Bianca
Roselli, Rosalinda
Finamore, Claudia
Biagioli, Michele
di Giorgio, Cristina
Bordoni, Martina
Conflitti, Paolo
Marchianò, Silvia
Bellini, Rachele
Rapacciuolo, Pasquale
Cassiano, Chiara
Limongelli, Vittorio
Sepe, Valentina
Catalanotti, Bruno
Fiorucci, Stefano
Zampella, Angela
Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
title Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
title_full Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
title_fullStr Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
title_full_unstemmed Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
title_short Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
title_sort discovery of a novel class of dual gpbar1 agonists–rorγt inverse agonists for the treatment of il-17-mediated disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933477/
https://www.ncbi.nlm.nih.gov/pubmed/36816679
http://dx.doi.org/10.1021/acsomega.2c07907
work_keys_str_mv AT fiorillobianca discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT rosellirosalinda discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT finamoreclaudia discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT biagiolimichele discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT digiorgiocristina discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT bordonimartina discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT conflittipaolo discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT marchianosilvia discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT bellinirachele discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT rapacciuolopasquale discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT cassianochiara discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT limongellivittorio discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT sepevalentina discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT catalanottibruno discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT fioruccistefano discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders
AT zampellaangela discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders